Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference 4caa2fd702
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.
Drug filings
21 acceptance records as first applicant, grouped into 12 source drug names. Source data as of 2026/11/13 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Sacubitril Valsartan Sodium Tablets 6 records · Latest accepted 2026/07/09
Supplement · 3Generic · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2601305 | Supplement | 2026/07/09 | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHB2601304 | Supplement | 2026/07/09 | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHB2601303 | Supplement | 2026/07/09 | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHS2400534 | Generic | 2024/02/06 | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHS2400533 | Generic | 2024/02/06 | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHS2400532 | Generic | 2024/02/06 | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Rosuvastatin Calcium and Ezetimibe Tablets (I) 1 records · Latest accepted 2026/05/12
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2600893 | Supplement | 2026/05/12 | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized; Fu Xing Pharmaceuticals (Xu Zhou) Co., Ltd. romanized | CDE ↗ |
Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ) 1 records · Latest accepted 2025/09/10
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2503344 | Generic | 2025/09/10 | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Iron Proteinsuccinylate Oral Solution 1 records · Latest accepted 2025/06/20
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2502227 | Generic | 2025/06/20 | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Ibuprofen Suspension 1 records · Latest accepted 2024/02/02
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2400439 | Generic | 2024/02/02 | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Rosuvastatin Calcium Tablets 2 records · Latest accepted 2024/01/17
Supplement · 2
Nifedipine Controlled-release Tablets 1 records · Latest accepted 2023/09/07
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2302410 | Generic | 2023/09/07 | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized; Qingdao Huang Hai Biopharmaceutical Co., Ltd. romanized | CDE ↗ |
Lactulose Oral Solution 2 records · Latest accepted 2023/08/15
Generic · 2
Empagliflozin Tablets 2 records · Latest accepted 2022/08/10
Generic · 2
Sildenafil Citrate Oral Disintegrating Tablets 1 records · Latest accepted 2022/04/06
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2200532 | Generic | 2022/04/06 | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized; Anhui Tai En Kang Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Febuxostat Tablets 2 records · Latest accepted 2021/12/11
Generic · 2
硝苯地平缓释片(II) · No verified English name 1 records · Latest accepted 2021/06/15
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2101388 | Supplement | 2021/06/15 | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Changes in the last 90 days
0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
Under review
2 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ) | CYHS2503344 | Generic | 2025/09/10 | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| Iron Proteinsuccinylate Oral Solution | CYHS2502227 | Generic | 2025/06/20 | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Catalogue holder records
16 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Sacubitril Valsartan Sodium Tablets | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | 国药准字H20254533 | 2025/06/10 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | 国药准字H20254532 | 2025/06/10 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | 国药准字H20254531 | 2025/06/10 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Nifedipine Controlled-release Tablets | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Qingdao Huang Hai Biopharmaceutical Co., Ltd. romanized | 国药准字H20249162 | 2024/10/22 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Empagliflozin Tablets | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | 国药准字H20234686 | 2023/12/26 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Empagliflozin Tablets | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | 国药准字H20234685 | 2023/12/26 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sildenafil Citrate Oral Disintegrating Tablets | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Anhui Tai En Kang Pharmaceutical Co., Ltd. romanized | 国药准字H20234296 | 2023/10/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Febuxostat Tablets | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | 国药准字H20233302 | 2023/03/21 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Febuxostat Tablets | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | 国药准字H20233303 | 2023/03/21 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Olmesartan Medoxomil Tablets | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | 国药准字H20223231 | 2022/04/19 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Olmesartan Medoxomil Tablets | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | 国药准字H20223232 | 2022/04/19 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Metronidazole Tablets | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | 国药准字H37021123 | 2021/11/23 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| 硝苯地平缓释片(II) · No verified English name | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | 国药准字H10910052 | 2021/04/20 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Rosuvastatin Calcium Tablets | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | 国药准字H20203569 | 2020/11/10 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rosuvastatin Calcium Tablets | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | 国药准字H20203568 | 2020/11/10 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rosuvastatin Calcium and Ezetimibe Tablets (I) | Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | Fu Xing Pharmaceuticals (Xu Zhou) Co., Ltd. romanized | 国药准字H20265978 | 2026/09/15 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
6 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Clopidogrel Hydrogen Sulphate Tablets | CYHB2601666 | Supplement | 2026/09/01 | Chongqing Hua Sen Pharmaceutical Co., Ltd. romanized; Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| Dronedarone Hydrochloride Tablets | CYHS2503637 | Generic | 2025/10/12 | Zhejiang Zhong Yan Pharmaceuticals Technology Co., Ltd. romanized; Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| Pioglitazone and Metformin Hydrochloride Tablets | CYHS2501972 | Generic | 2025/06/04 | Zhejiang Zhong Yan Pharmaceuticals Technology Co., Ltd. romanized; Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| Sitagliptin Phosphate and Metformin Hydrochloride Tablets (II) | CYHS2500934 | Generic | 2025/03/06 | Beijing Yuan Yan Pharmaceuticals Technology Co., Ltd. romanized; Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| Clopidogrel Hydrogen Sulphate Tablets | CYHS2404085 | Generic | 2024/11/28 | Zhejiang Zhong Yan Pharmaceuticals Technology Co., Ltd. romanized; Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| Metformin Hydrochloride Extended-release Tablets | CYHS2200428 | Generic | 2022/03/11 | Qingdao Huang Hai Biopharmaceutical Co., Ltd. romanized; Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
- Full API register
- Last successful update: 2026/11/13 06:41
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.